Hereditary Corneal Dystrophies (ICD-11: 9A70)

1. Introduction

Hereditary corneal dystrophies represent a heterogeneous group of genetic conditions that affect the transparency and structure of the cornea, the most anterior and transparent layer of the eye. These conditions are characterized by progressive opacification and, in some cases, vascularization of the cornea, frequently associated with macular hypoplasia. Unlike keratitis acquired from infectious, traumatic, or environmental causes, hereditary corneal dystrophies have a genetic origin and are transmitted in an autosomal dominant manner, primarily through mutations in the PAX6 gene.

The clinical importance of these dystrophies lies in their potential to cause significant visual impairment, which may manifest from childhood to adulthood, depending on the specific type and severity of the genetic mutation involved. The presence of macular hypoplasia and iris anomalies in some familial cases suggests that certain forms of these dystrophies may represent manifestations of aniridia, a congenital condition characterized by partial or complete absence of the iris.

The exact prevalence of hereditary corneal dystrophies remains unknown, although they are considered rare conditions in general ophthalmologic practice. The impact on public health is significant due to the progressive nature of the disease and the potential for bilateral visual impairment, affecting quality of life, work capacity, and functional independence of affected patients.

Correct coding of these conditions is critical for various aspects of medical care: it enables appropriate epidemiological tracking, facilitates research on treatments and prognosis, ensures appropriate reimbursement in health systems, enables family genetic counseling, and contributes to resource planning in specialized ophthalmology services.

2. Correct ICD-11 Code

Code: 9A70

Description: Hereditary dystrophies of the cornea

Parent category: Disorders of the cornea

Official definition: Hereditary corneal dystrophy (hereditary keratitis) is characterized by corneal opacification and vascularization, frequently associated with macular hypoplasia. The prevalence is unknown. The syndrome is transmitted in an autosomal dominant manner and is associated with mutations in the PAX6 gene. The presence of macular hypoplasia and iris anomalies in some familial cases suggests that, in these cases, the disease may be a form of aniridia.

This specific code was developed in ICD-11 to clearly distinguish genetic corneal dystrophies from other forms of acquired corneal involvement. The explicit inclusion of the association with the PAX6 gene reflects advances in genetic-molecular knowledge of ophthalmologic diseases and allows for more precise classification based on etiology.

Code 9A70 should be used when there is confirmation or strong clinical suspicion of a hereditary corneal dystrophy, especially when there is positive family history, identifiable autosomal dominant inheritance pattern, or when genetic testing confirms mutations in the PAX6 gene. Adequate documentation of the hereditary pattern and specific clinical characteristics is essential for the correct application of this code.

3. When to Use This Code

The code 9A70 should be applied in specific clinical situations where the hereditary and genetic characteristics of corneal dystrophy are evident:

Scenario 1: Patient with positive family history and bilateral corneal opacification A 25-year-old patient presents with progressive bilateral decrease in visual acuity, with ophthalmologic examination revealing diffuse corneal opacification in both eyes. Family history reveals that the father and paternal grandmother have a similar condition, suggesting an autosomal dominant inheritance pattern. In this case, code 9A70 is appropriate even before genetic confirmation, provided that other acquired causes have been excluded.

Scenario 2: Child with congenital corneal opacification associated with iris anomalies A 3-year-old child is evaluated for low vision and presents with bilateral corneal opacification associated with iris hypoplasia and nystagmus. Examination also reveals foveal hypoplasia on optical coherence tomography. The mother presents with similar but milder features. This presentation suggests hereditary corneal dystrophy possibly related to a form of aniridia, justifying the use of code 9A70.

Scenario 3: Adult with diagnosis confirmed by genetic testing A 40-year-old patient with progressive corneal opacification undergoes genetic testing that confirms a mutation in the PAX6 gene. Even without known family history (possible de novo mutation or undocumented family history), genetic confirmation fully justifies the use of code 9A70.

Scenario 4: Patient with progressive corneal vascularization and family pattern A 16-year-old adolescent presents with superficial bilateral corneal vascularization, with documented progression over the past 5 years. Two siblings present with a similar condition at different stages. Investigation excludes infectious, inflammatory, or traumatic causes, and the family pattern suggests hereditary dystrophy, warranting code 9A70.

Scenario 5: Follow-up of patient with established diagnosis A patient with a previous diagnosis of hereditary corneal dystrophy returns for follow-up consultation. Even if there are no significant changes on current examination, code 9A70 should be used to document the underlying condition and allow for appropriate longitudinal follow-up.

Scenario 6: Pre-corneal transplant evaluation A patient with advanced hereditary corneal dystrophy is evaluated for possible corneal transplant (keratoplasty). Code 9A70 should be used to document the primary indication for the procedure, even if additional codes are necessary to describe complications or associated procedures.

4. When NOT to Use This Code

It is essential to distinguish hereditary corneal dystrophies from other conditions that affect the cornea but have different etiology:

Infectious keratitis: Corneal opacifications caused by bacteria, viruses, fungi, or parasites should not be coded as 9A70. These conditions have acute or subacute onset, are usually unilateral, present inflammatory signs such as pain, hyperemia, and discharge, and require specific codes for infectious keratitis (9A71 or specific subcategories).

Traumatic keratitis: Corneal injuries resulting from ocular trauma, including abrasions, lacerations, or chemical burns, even if resulting in permanent opacification, are not hereditary dystrophies and require appropriate coding for traumatic keratitis (9A72) or sequelae of ocular trauma.

Acquired corneal degenerations: Conditions such as pellucid marginal degeneration, keratoconus (when there is no documented hereditary component), or age-related degenerations should not be coded as 9A70. Although some of these conditions may have a genetic component, they have their own classification in ICD-11.

Secondary corneal opacifications: Corneal scars resulting from previous surgeries, resolved infections, or systemic diseases (such as vitamin A deficiency) are not hereditary dystrophies and require codes that reflect the primary cause or sequela.

Specific corneal dystrophies already classified: Some specific corneal dystrophies, such as Fuchs dystrophy, granular dystrophy, or lattice dystrophy, may have more specific codes in ICD-11. When available, the more specific code should be preferred over the generic code 9A70.

Code 9A70 should also not be used in isolation when the condition is clearly part of a broader genetic syndrome that has its own coding, such as complete aniridia, where the code for the primary syndrome would be more appropriate.

5. Step-by-Step Coding Process

Step 1: Assess diagnostic criteria

The first step in proper coding is to confirm that the patient meets the diagnostic criteria for hereditary corneal dystrophy:

Ophthalmologic clinical evaluation: Perform a complete ophthalmologic examination including visual acuity, slit-lamp biomicroscopy to evaluate the cornea in detail, identifying opacification patterns, presence of vascularization, and characteristics of the distribution of changes. Also examine the iris to identify structural anomalies.

Detailed family history: Carefully investigate the presence of similar ocular conditions in first, second, and third-degree relatives. Construct a pedigree when possible to identify the inheritance pattern. Specifically ask about visual problems, previous ocular surgeries, and use of glasses or contact lenses in the family.

Complementary examinations: Consider corneal topography or tomography to document structural changes, specular microscopy to evaluate the corneal endothelium, anterior segment optical coherence tomography (OCT) to evaluate corneal layers, and macular OCT to identify macular hypoplasia when present.

Genetic evaluation: When available and indicated, genetic testing for mutations in the PAX6 gene can definitively confirm the diagnosis. This test is particularly useful in cases without clear family history or when genetic counseling is needed.

Step 2: Verify specifiers

Document the specific characteristics of the presentation:

Severity: Classify visual impairment as mild (visual acuity better than 20/40), moderate (20/40 to 20/200), or severe (worse than 20/200). Document whether there is significant functional impairment.

Laterality: Specify whether the condition is unilateral or bilateral. Hereditary dystrophies are typically bilateral, although they may be asymmetric.

Progression: Document whether the condition is stable, slowly progressive, or rapidly progressive, based on previous examinations when available.

Associated features: Record the presence of macular hypoplasia, iris anomalies, nystagmus, or other associated ocular manifestations that may suggest a broader syndrome.

Step 3: Differentiate from other codes

9A71 - Infectious keratitis: The key difference is the presence of an identifiable infectious agent, acute or subacute onset, active inflammatory signs (pain, hyperemia, photophobia), usually unilateral, and response to specific antimicrobial treatment. Hereditary dystrophies have insidious onset, are bilateral, and do not respond to antibiotics.

9A72 - Traumatic keratitis: Distinguished by a clear history of ocular trauma preceding corneal opacification. Usually unilateral, with an opacification pattern corresponding to the trauma mechanism. Hereditary dystrophies have no precipitating traumatic event.

9A73 - Exposure keratitis: Results from inadequate eyelid closure (lagophthalmos), leading to desiccation and corneal opacification, typically in the interpalpebral area. There is an identifiable cause for the exposure (facial paralysis, ectropion, exophthalmos). Hereditary dystrophies have no relationship with corneal exposure.

Other specific corneal dystrophies: If there are clinical or genetic characteristics that identify a specific dystrophy (such as Fuchs dystrophy, granular, or lattice), use the more specific code when available in ICD-11.

Step 4: Required documentation

Checklist of mandatory information:

• Detailed description of corneal changes observed on biomicroscopy
• Visual acuity with and without correction in both eyes
• Complete family history with pedigree when possible
• Results of complementary examinations (topography, tomography, specular microscopy)
• Exclusion of acquired causes (infection, trauma, exposure)
• Presence or absence of associated anomalies (iris, macula)
• Results of genetic tests when performed
• Identified or presumed inheritance pattern
• Evaluation of other family members when available

How to document properly:

In the medical record, document the clinical presentation in narrative form, followed by objective examination findings. Include images when possible (anterior segment photographs, topographies). In the diagnosis field, record "Hereditary corneal dystrophy" followed by specific characteristics (example: "bilateral, moderately severe, with associated macular hypoplasia"). In the coding field, enter code 9A70, adding complementary codes for complications or procedures when applicable.

6. Complete Practical Example

Clinical Case:

Marina, 28 years old, seeks ophthalmologic consultation reporting progressive vision decrease in both eyes over the last 5 years. She reports that her father and paternal grandfather have similar visual problems, both having undergone corneal transplantation. She denies ocular trauma, previous ocular infections, or chronic topical medication use.

On ophthalmologic examination, best-corrected visual acuity is 20/80 in the right eye and 20/100 in the left eye. Biomicroscopy reveals diffuse corneal stromal opacification in both eyes, more pronounced centrally, with the presence of fine superficial blood vessels at the corneal periphery. The iris shows discrete hypoplasia with positive transillumination. Fundus examination reveals absence of bilateral foveal reflex.

Anterior segment optical coherence tomography demonstrates corneal stromal thickening and irregularity. Macular OCT confirms bilateral foveal hypoplasia. Corneal topography shows diffuse irregularity without specific ectasia pattern. Specular microscopy reveals polymegathism and endothelial pleomorphism.

Detailed family history reveals that Marina's father was diagnosed with "hereditary corneal disease" at age 35 and underwent bilateral transplantation at age 45. The paternal grandfather had a similar condition. Marina's sister, age 25, has no symptoms yet but has never been evaluated by an ophthalmologist. The family pattern suggests autosomal dominant inheritance.

Based on clinical presentation, family history, and complementary examination findings, genetic testing was requested which confirmed a mutation in the PAX6 gene. Marina was referred for genetic counseling and her sister was called for preventive ophthalmologic evaluation.

Step-by-Step Coding:

Criteria Analysis:

1. Bilateral corneal opacification: Present, confirmed by biomicroscopy and corneal tomography
2. Corneal vascularization: Present, peripheral superficial vessels observed
3. Positive family history: Father and paternal grandfather affected, autosomal dominant pattern
4. Macular hypoplasia: Confirmed by macular OCT
5. Iris anomalies: Mild hypoplasia present
6. Genetic confirmation: PAX6 gene mutation identified
7. Exclusion of acquired causes: No history of infection, trauma, or exposure

Code Selected: 9A70 - Hereditary corneal dystrophies

Complete Justification:

Code 9A70 is the most appropriate for this case because:

• The patient presents all cardinal characteristics of hereditary corneal dystrophy: bilateral corneal opacification, vascularization, macular hypoplasia, and iris anomalies
• The autosomal dominant inheritance pattern is clearly documented through three affected generations
• Genetic confirmation with PAX6 gene mutation is consistent with the official definition of code 9A70
• Acquired causes of corneal opacification were adequately excluded by clinical history and examination
• The presence of macular hypoplasia and iris anomalies suggests possible relationship with aniridia, as mentioned in the code definition
• The progressive and bilateral nature of the condition is typical of hereditary dystrophies

Applicable Complementary Codes:

• Code for macular hypoplasia (if specific code available in ICD-11)
• Code for iris anomalies (if additional coding is necessary for complete documentation purposes)
• Procedure codes when Marina undergoes corneal transplantation in the future

Medical Record Documentation:

"28-year-old patient with hereditary corneal dystrophy (ICD-11: 9A70), confirmed by positive genetic testing for PAX6 gene mutation. Typical clinical presentation with bilateral corneal opacification and vascularization, associated with macular hypoplasia and mild iris anomalies. Strongly positive family history with autosomal dominant inheritance pattern (father and paternal grandfather affected). Moderate bilateral visual impairment (VA 20/80 OD, 20/100 OS). Patient counseled regarding progressive nature of the condition, prognosis, future therapeutic options including possible corneal transplantation, and importance of genetic counseling. Sister called for preventive evaluation."

7. Related Codes and Differentiation

Within the Same Category:

9A71: Infectious keratitis

When to use vs. 9A70: Use 9A71 when there is evidence of an infectious agent (bacterial, viral, fungal, or parasitic) causing corneal inflammation. Typical presentation includes acute onset, intense ocular pain, photophobia, discharge, conjunctival hyperemia, and corneal infiltrate with inflammatory reaction.

Main difference: Infectious keratitis is an acquired condition, usually unilateral, with acute onset and prominent inflammatory signs, whereas hereditary dystrophy (9A70) is bilateral, with insidious onset, progressive, without active inflammatory signs, and has proven or presumed genetic basis.

9A72: Traumatic keratitis

When to use vs. 9A70: Apply 9A72 when corneal opacification or injury results from direct ocular trauma, including abrasions, lacerations, foreign bodies, or chemical or thermal burns. A history of trauma preceding corneal changes is essential.

Main difference: Traumatic keratitis has an identifiable traumatic event as the cause, is usually unilateral, and the pattern of corneal injury corresponds to the mechanism of trauma. Hereditary dystrophy (9A70) has no relationship to trauma, is bilateral and symmetric, and has progression independent of external events.

9A73: Exposure keratitis

When to use vs. 9A70: Use 9A73 when corneal changes result from inadequate eyelid closure, leading to desiccation of the ocular surface. Causes include facial nerve paralysis, ectropion, severe exophthalmos, or corneal anesthesia.

Main difference: Exposure keratitis has an identifiable mechanical cause (inadequate exposure), presents typical changes in the interpalpebral area, and improves with adequate ocular protection. Hereditary dystrophy (9A70) has no relationship to exposure, affects the entire cornea more uniformly, and does not respond to ocular protection measures.

Differential Diagnoses:

Keratoconus: Although it may have a hereditary component, keratoconus is characterized by corneal thinning and conical protrusion, not by diffuse opacification. It has a specific code in ICD-11 and should not be confused with opacifying hereditary dystrophies.

Aniridia: Complete aniridia is a distinct condition characterized by absence or severe hypoplasia of the iris. Although it may be associated with corneal changes and also involves mutations in the PAX6 gene, when aniridia is the dominant manifestation, its specific code should be used. Code 9A70 is more appropriate when corneal dystrophy is the main manifestation.

Specific corneal dystrophies: Dystrophies such as Fuchs (endothelial), granular, lattice, or macular have specific clinical presentations and histopathological patterns. When identified, they should receive their specific codes rather than the generic code 9A70.

Metabolic corneal opacifications: Conditions such as mucopolysaccharidoses or other storage diseases may cause corneal opacification. In these situations, the code for the primary metabolic disease is more appropriate, with corneal involvement being documented as a secondary manifestation.

8. Differences with ICD-10

In ICD-10, hereditary corneal dystrophies were coded primarily under the code H18.5 - Hereditary dystrophies of cornea, with subcategories for specific types such as H18.50 (hereditary corneal dystrophy, unspecified), H18.51 (corneal endothelial dystrophy), H18.52 (corneal epithelial dystrophy), among others.

Main changes in ICD-11:

The transition to code 9A70 in ICD-11 represents a more refined and scientifically updated approach:

1. Explicit genetic basis: ICD-11 explicitly incorporates the association with mutations in the PAX6 gene in the official definition, reflecting advances in the genetic-molecular knowledge of corneal dystrophies.

2. Relationship with aniridia: The new classification formally recognizes the possible relationship between certain hereditary corneal dystrophies and forms of aniridia, based on the presence of macular hypoplasia and iris anomalies.

3. Modified hierarchical structure: ICD-11 uses a more logical and flexible structure, facilitating the addition of specific subcategories as new genetic subtypes are identified.

4. Updated terminology: The inclusion of the term "hereditary keratitis" as a synonym reflects contemporary clinical use, although "dystrophy" remains the preferred term.

Practical impact of these changes:

For healthcare professionals, the main practical change is the need to document in greater detail the genetic basis of the condition when possible. The performance of genetic testing, when available, becomes more relevant not only for diagnosis, but also for appropriate coding.

For health information systems, the transition requires updating databases and training coders to recognize the new definitions and criteria. Greater genetic specificity allows better epidemiological tracking and identification of patients for clinical studies or genetic counseling programs.

For reimbursement and resource management purposes, more precise coding can facilitate the justification of genetic testing and specialized treatments, including corneal transplants when indicated.

9. Frequently Asked Questions

1. How is the diagnosis of hereditary corneal dystrophies made?

The diagnosis is established through a combination of detailed clinical ophthalmological evaluation, careful family history, and, when available, genetic confirmation. The ophthalmological examination includes slit-lamp biomicroscopy to visualize corneal changes, visual acuity assessment, and complementary tests such as corneal topography, optical coherence tomography, and specular microscopy. Family history is crucial and should investigate the presence of similar ocular conditions across multiple generations. Genetic testing for mutations in the PAX6 gene can definitively confirm the diagnosis, being particularly useful in cases without clear family history or when genetic counseling is needed for family planning.

2. Is treatment available in public health systems?

Treatment availability varies significantly among different regions and health systems. Regular ophthalmological follow-up is generally available in public ophthalmology services. Conservative treatments, such as artificial tears for ocular comfort and glasses for refractive error correction, are widely accessible. However, more specialized treatments, such as corneal transplantation (keratoplasty), may have limited availability in some public systems, with possible waiting lists. Genetic testing may not be routinely available in all public services, but can be accessed through research programs or specialized medical genetics centers.

3. How long does treatment last?

Hereditary corneal dystrophies are chronic and progressive conditions that require ophthalmological follow-up throughout life. There is no definitive "cure," but treatment aims to preserve functional vision for as long as possible. Initial follow-up may be semiannual or annual, depending on severity and progression rate. Conservative treatments are continuous. When corneal transplantation is indicated, the surgical procedure is performed in a single stage, but postoperative follow-up is prolonged, with frequent visits in the first year and permanent follow-up to monitor graft transparency and prevent rejection. Topical immunosuppressive medications may be necessary for prolonged periods after transplantation.

4. Can this code be used in medical certificates?

Yes, code 9A70 can and should be used in medical certificates when hereditary corneal dystrophy causes functional limitation that justifies absence from work or school activities. This may occur during periods of acute visual decompensation, in the perioperative period of corneal surgeries (including transplantation), or when visual impairment is severe enough to prevent safe performance of certain professional activities. In medical certificates, it is recommended to include not only the ICD code but also a clear description of the functional limitation and its relationship to the patient's activity demands. For purposes of long-term benefits or disability retirement, additional documentation may be necessary including visual acuity assessment, visual field, and functional capacity.

5. Can the condition skip generations in the family?

Although hereditary corneal dystrophies associated with the PAX6 gene are typically transmitted in an autosomal dominant manner (meaning that affected individuals usually have an affected parent), there are situations where the condition may appear to "skip" generations. This can occur due to incomplete penetrance (when an individual carries the mutation but does not develop significant clinical manifestations), variable expressivity (when manifestations are so mild in one generation that they go unnoticed), or de novo mutations (new mutations that occur spontaneously). Additionally, in large families, there may be unaffected family branches by chance. Genetic counseling is essential to clarify the specific inheritance pattern in each family and estimate risks for descendants.

6. Should children of affected parents be examined preventively?

Yes, it is highly recommended that children of individuals with confirmed hereditary corneal dystrophy undergo preventive ophthalmological evaluation, ideally during childhood. Early examination allows identification of initial manifestations of the condition, establishment of a baseline for future comparisons, and implementation of appropriate follow-up measures. The frequency of follow-up will depend on initial findings: children without manifestations may be re-evaluated annually or biennially, while those with initial changes may require more frequent follow-up. Early identification also allows appropriate educational and vocational planning, considering possible future visual limitations.

7. Are there preventive measures to slow progression?

Currently, there are no proven measures to prevent or significantly slow the progression of hereditary corneal dystrophies, as they are genetically determined. However, some general ocular health measures may be beneficial: protection against ocular trauma using protective eyewear during high-risk activities, adequate ocular lubrication to maintain healthy ocular surface, protection against ultraviolet radiation using UV-filtered glasses, avoiding contact lens use when there is significant corneal compromise (risk of complications), and appropriate treatment of any ocular infection to prevent additional damage. Regular ophthalmological follow-up is essential to detect complications early and optimize the timing of interventions such as corneal transplantation.

8. Does corneal transplantation definitively cure the condition?

Corneal transplantation (penetrating or lamellar keratoplasty) can significantly restore vision in patients with advanced-stage hereditary corneal dystrophies by replacing opacified corneal tissue with transparent donor tissue. However, it is not a "cure" in the sense of eliminating genetic predisposition. In some types of dystrophies, there may be disease recurrence in the graft over the years, although this is less common in dystrophies associated with the PAX6 gene. Additionally, transplantation carries risks such as graft rejection, infection, and need for prolonged use of immunosuppressive medications. Despite these limitations, corneal transplantation has high success rates and can provide substantial and lasting visual improvement for many patients, often being the best therapeutic option when visual impairment is significant.

---

Conclusion:

Appropriate coding of hereditary corneal dystrophies using ICD-11 code 9A70 requires detailed understanding of the clinical, genetic, and familial characteristics of this condition. Careful documentation of family history, specific clinical findings, and, when possible, genetic confirmation, is essential for correct application of this code. Clear distinction from other forms of acquired corneal compromise ensures diagnostic accuracy and facilitates appropriate management, including family genetic counseling and long-term therapeutic planning. With continued advancement in genetic-molecular knowledge of ophthalmological diseases, ICD-11 offers a more robust and scientifically grounded framework for the classification of these complex conditions.

External References

This article was prepared based on reliable scientific sources:

1. 🌍 WHO ICD-11 - Hereditary corneal dystrophies
2. 🔬 PubMed Research on Hereditary corneal dystrophies
3. 🌍 WHO Health Topics
4. 📊 Clinical Evidence: Hereditary corneal dystrophies
5. 📋 Ministry of Health - Brazil
6. 📊 Cochrane Systematic Reviews

References verified on 2026-02-04